AMRI Completes Acquisition of Euticals
ALBANY, N.Y., July 11, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Prime European Therapeuticals S.p.A., also known as "Euticals", a privately-held company headquartered inLodi, Italy, specializing in custom synthesis and the manufacture of ac...
AMRI to Acquire Euticals in a Strategic Transaction That Expands its API Development and Manufacturing Business
ALBANY, N.Y., May 5, 2016 /PRNewswire/ -- * Enters definitive agreement to acquire Euticals for $358 million in stock, cash and a seller note * Positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry * Significantly expands AMRI's pre...
AMRI Acquires Whitehouse Laboratories
ALBANY, New York, Dec. 15, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has acquired all the outstanding equity interests of Whitehouse Laboratories, a leading provider of testing services that includes chemical and material analysis, method development and validation and qual...
AMRI Announces Third Quarter 2015 Results
ALBANY, N.Y., Nov. 5, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the third quarter endedSeptember 30 2015. Highlights: * Third quarter contract revenue of $101.4 million, a 76% increase from 2014 * Adjusted contract margins expand to 25% * Th...
AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients
ALBANY, New York, Aug. 31, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients, ("APIs"). The collaboration combi...
AMRI Announces Second Quarter 2015 Results
ALBANY, N.Y., Aug. 4, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the second quarter endedJune 30, 2015. Highlights: * Second quarter contract revenue of $85.2 million, a 39% increase from 2014 * Adjusted contract margins of 26% * Second quart...
AMRI Acquires Gadea Pharmaceutical Group
ALBANY, New York, July 16, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately-held company located in Valladolid,Spain, specializing in technically complex active pharmaceutical ingredients (APIs) an...
AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation and Commercialization Hub
BUFFALO, N.Y., June 17, 2015 /PRNewswire/ -- As further evidence of Governor Andrew M. Cuomo's successful establishment of a dynamic and growing bio-pharma sector inBuffalo, New York, Albany Molecular Research Inc. (NASDAQ: AMRI) and PerkinElmer, Inc. today announced the formation of a strategic ...
AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y.
BUFFALO, N.Y., June 1, 2015 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that it has signed a collaborative agreement with biotechnology company HarkerBIO LLC to co-market their structure-based drug discovery services to global pharmaceutical and biotechno...
AMRI Announces First Quarter 2015 Results
ALBANY, New York, May 5, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter endedMarch 31, 2015. Highlights: * First quarter contract revenue of $75.1 million, up 47% from 2014 * First quarter royalties of $6.7 million, down 19% fro...
AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
ALBANY, N.Y., May 1, 2015 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today thatWilliam S. Marth, AMRI's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference onWednesday, May 13, 2015 at 4:20 p.m. ET. A l...
AMRI to Close Holywell, U.K. API Manufacturing Facility
ALBANY, N.Y., April 3, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturin...
AMRI Hires VP of International Sales
ALBANY, New York, March 5, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today thatMichael Pettersson, fills the newly created position of VP of International Sales, effective immediately. He reports toChristopher Conway, Senior Vice President of Global Sales and Marketing. In this role, Mr...
AMRI Realigns Global Operations to Enhance Continuous Supply Chain for Customers
ALBANY, N.Y., Feb. 13, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has implemented several changes to further optimize global business operations in order to enhance continuity from early development through to commercial supply and accelerate the company's global growth obje...
AMRI Announces Fourth Quarter and Full Year 2014 Results
ALBANY, N.Y., Feb. 12, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2014. "While our OsoBio facility resumed full operations later than anticipated, after we learned in the fall of 2014 that a remed...
AMRI Receives NIH Contract Award for the Formulation Development and Manufacture of Pre-Clinical and Clinical Drug Product
ALBANY, New York, Jan. 19, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it received a 10-year federal contract award from the National Institutes of Health (NIH) for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke (NINDS) a...
AMRI Announces CFO Transition
ALBANY, New York, Jan. 12, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced thatMichael M. Nolan, senior vice president and chief financial officer, will be departing AMRI. Mr. Nolan will remain with AMRI through February 2015 to support an orderly transition. The company also announced ...
AMRI Announces Agreement with Genovi Pharmaceuticals Limited for Development and Manufacturing of Parenteral Drug Products
ALBANY, N.Y., Jan. 12, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has entered into several development and supply agreements with Genovi Pharmaceuticals Limited ("Genovi"), a specialty generic pharmaceutical company, to manufacture select generic parenteral drug products...
Aptuit to Divest Two Non-Core Sites; Facilitates Reinvestment and Accelerated Growth in Core Area of Integrated Solutions
GREENWICH, Conn., Jan. 9, 2015 /PRNewswire/ -- Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit has divested its aseptic clinical manufacturing site inGlasgow, UK to Albany Molecular Research, Inc. (NASDAQ: AMRI), and has entered into a definitive agreement with AMRI to acq...
AMRI to Acquire Aptuit Drug Product Development and Aseptic Clinical Manufacturing Businesses
ALBANY, New York, Jan. 9, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has acquired the outstanding equity interests of Aptuit's Glasgow, UK business and has entered into a definitive agreement to acquire Aptuit's SSCI/West Lafayette, Ind. business for total consideration of $6...
